Current and Emerging Bispecifics in Multiple Myeloma: Clinical Data Review

A panel of experts on multiple myeloma discuss the importance of GPRC5D as a target of interest in relapsed/refractory disease and discuss their experiences with talquetamab in clinical practice.

Larysa J. Sanchez, MD, discusses recent efficacy data presented at EHA 2024 from the long-term follow-up results of the phase 1/2 MonumenTAL-1 study investigating talquetamab in relapsed/refractory multiple myeloma.

Noopur Raje, MD, shares clinical perspectives on her experience treating patients with prior BCMA bispecific exposure and provides insights on adverse event management practices in patients receiving talquetamab.

Hematologist-oncologists discuss GPRC5D-targeting treatments that are currently in development for patients with relapsed/refractory multiple myeloma.

Rafael Fonseca, MD, discusses the MonumenTAL-2 and MonumenTAL-3 clinical trials investigating talquetamab combination strategies in relapsed/refractory multiple myeloma.

Focusing on clinical trials evaluating combination strategies with bispecifics, Larysa J. Sanchez, MD, discusses the TRIMM-2, TRIMM-3, and MajesTEC-3 studies.

Experts highlighted the use of GPRC5D therapy in patients with multiple myeloma.

Noopur Raje, MD, reviews clinical research on elranatamab combination therapy in patients with relapsed/refractory multiple myeloma.

Rafael Fonseca, MD, discusses the role of bispecifics in relapsed/refractory multiple myeloma and the implications of incorporating them into combination regimens.

The panel discusses the benefits of having multiple BCMA-targeting bispecifics available for patients with relapsed/refractory multiple myeloma.

Noopur Raje, MD, discusses the role of T-cell affinity in bispecific therapy for patients with relapsed/refractory multiple myeloma and how it impacts treatment practices.